{"analyses":[{"ciLowerLimit":"0.63","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.21","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4134","paramType":"Hazard Ratio (HR)","paramValue":"0.87","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.05","groupIds":["OG002","OG003"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.87"},{"ciLowerLimit":"0.73","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.99","groupIds":["OG004","OG005"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.85"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.4","upperLimit":"12.2","value":"10.6"},{"groupId":"OG001","lowerLimit":"8.6","upperLimit":"15.5","value":"11.1"},{"groupId":"OG002","lowerLimit":"7.4","upperLimit":"9.5","value":"8.2"},{"groupId":"OG003","lowerLimit":"8.2","upperLimit":"10.9","value":"8.9"},{"groupId":"OG004","lowerLimit":"7.2","upperLimit":"8.6","value":"8.0"},{"groupId":"OG005","lowerLimit":"7.8","upperLimit":"9.6","value":"8.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"116"},{"groupId":"OG002","value":"309"},{"groupId":"OG003","value":"316"},{"groupId":"OG004","value":"464"},{"groupId":"OG005","value":"467"}],"units":"Participants"}],"description":"OS was defined as time from randomization to death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG000","title":"IC2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC2/3","id":"OG001","title":"IC2/3 Atezolizumab"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG002","title":"IC1/2/3 Chemotherapy"},{"description":"PD-L1 immunohistochemistry (IHC) score of IC1/2/3","id":"OG003","title":"IC1/2/3 Atezolizumab"},{"description":"Participants randomized to the chemotherapy arm received vinflunine, paclitaxel, or docetaxel per the investigators choice. Vinflunine 320 milligrams per square meter (mg/m\\^2), paclitaxel 175 mg/m\\^2, or docetaxel 75 mg/m\\^2 were administered intravenously on Day 1 of each 21-day cycle until disease progression per standard RECIST v1.1 or unacceptable toxicity.","id":"OG004","title":"Chemotherapy (Vinflunine, Paclitaxel, or Docetaxel)"},{"description":"Atezolizumab was administered intravenously at a fixed dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Participants received atezolizumab as long as they continued to experience clinical benefit in the opinion of the investigator until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator.","id":"OG005","title":"Atezolizumab"}],"paramType":"MEDIAN","populationDescription":"Intent To Treat (ITT) was defined as all randomized participants, irrespective of whether the assigned treatment was actually received.","reportingStatus":"POSTED","timeFrame":"Between randomization and death due to any cause, up to approximately 25 months after first participant enrolled","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"Months"}